Africa and Middle East Cardiovascular Epidemiological Study (ACE)

February 17, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region

This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.

Study Overview

Status

Completed

Conditions

Detailed Description

This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.

Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.

Study Type

Observational

Enrollment (Actual)

4386

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Algeria
      • Alger, Algeria, 16015
        • Pfizer Investigational Site
      • Bejaja, Algeria, 6000
        • Pfizer Investigational Site
      • Djelfa, Algeria, 17000
        • Pfizer Investigational Site
      • Laghouat, Algeria
        • Pfizer Investigational Site
      • M'Sila, Algeria
        • Pfizer Investigational Site
      • Relizane, Algeria, 48000
        • Pfizer Investigational Site
      • Saida, Algeria, 20000
        • Pfizer Investigational Site
      • Tebessa, Algeria
        • Pfizer Investigational Site
      • Tlemcen, Algeria, 13000
        • Pfizer Investigational Site
  • Cameroon
      • Bafoussam, Cameroon
        • Pfizer Investigational Site
      • Mbandjock, Cameroon
        • Pfizer Investigational Site
      • Njombe, Cameroon
        • Pfizer Investigational Site
      • Soa, Cameroon
        • Pfizer Investigational Site
    • Cite Verte
      • Yaounde, Cite Verte, Cameroon
        • Pfizer Investigational Site
    • Deido
      • Douala, Deido, Cameroon
        • Pfizer Investigational Site
  • Egypt
      • Alexandria, Egypt
        • Pfizer Investigational Site
      • Cairo, Egypt
        • Pfizer Investigational Site
      • Shiben Al Kom, Egypt
        • Pfizer Investigational Site
      • Tanta, Egypt
        • Pfizer Investigational Site
  • Ghana
      • Accra, Ghana
        • Pfizer Investigational Site
      • Jachie-Ashanti, Ghana
        • Pfizer Investigational Site
      • Kumasi, Ghana
        • Pfizer Investigational Site
      • Sogakope V/R, Ghana
        • Pfizer Investigational Site
      • Takoradi, Ghana
        • Pfizer Investigational Site
  • Jordan
      • Amman, Jordan
        • Pfizer Investigational Site
      • Irbid, Jordan
        • Pfizer Investigational Site
      • Salt, Jordan
        • Pfizer Investigational Site
  • Kenya
      • Chongoria, Kenya, 60401
        • Pfizer Investigational Site
      • Nairobi, Kenya, 00508
        • Pfizer Investigational Site
  • Kuwait
      • Adailiya, Kuwait
        • Pfizer Investigational Site
      • Fahaheel, Kuwait
        • Pfizer Investigational Site
      • Kuwait, Kuwait
        • Pfizer Investigational Site
      • Mishref, Kuwait
        • Pfizer Investigational Site
      • Qadesya, Kuwait
        • Pfizer Investigational Site
      • Yarmouk, Kuwait
        • Pfizer Investigational Site
  • Lebanon
      • Beirut, Lebanon
        • Pfizer Investigational Site
      • Jbeil, Lebanon, Lebanon
        • Pfizer Investigational Site
      • Jounieh, Lebanon
        • Pfizer Investigational Site
      • Tripoli, Lebanon
        • Pfizer Investigational Site
  • Nigeria
      • Abuja, FCT, Nigeria
        • Pfizer Investigational Site
      • Abuja, Garki, Nigeria
        • Pfizer Investigational Site
      • Calabar, Nigeria
        • Pfizer Investigational Site
      • Enugu, Nigeria
        • Pfizer Investigational Site
      • Keffi, Nassarawa, Nigeria
        • Pfizer Investigational Site
  • Saudi Arabia
      • Dammam, Saudi Arabia
        • Pfizer Investigational Site
      • Jeddah, Saudi Arabia
        • Pfizer Investigational Site
      • Jeddah 21573, Saudi Arabia
        • Pfizer Investigational Site
      • Makkah, Saudi Arabia
        • Pfizer Investigational Site
      • Riyadh, Saudi Arabia
        • Pfizer Investigational Site
      • Riyadh, Saudi Arabia, 11584
        • Pfizer Investigational Site
      • Yanbu, Saudi Arabia
        • Pfizer Investigational Site
  • Senegal
      • Kebemer, Senegal
        • Pfizer Investigational Site
      • Kedoungou, Senegal
        • Pfizer Investigational Site
      • Saint Louis, Senegal
        • Pfizer Investigational Site
      • Ziguinchor, Senegal
        • Pfizer Investigational Site
    • Nabil Choucair
      • Dakar, Nabil Choucair, Senegal
        • Pfizer Investigational Site
    • Ouakam
      • Dakar, Ouakam, Senegal
        • Pfizer Investigational Site
  • South Africa
      • Kwa-Zulu Natal, South Africa, 4091
        • Pfizer Investigational Site
      • Rondebosch, South Africa, 7700
        • Pfizer Investigational Site
    • Gauteng
      • Halfway House, Gauteng, South Africa, 1685
        • Pfizer Investigational Site
    • Kwazulu-natal
      • Sydenham, Durban, Kwazulu-natal, South Africa, 4091
        • Pfizer Investigational Site
    • Limpopo
      • Mokopane, Limpopo, South Africa, 0600
        • Pfizer Investigational Site
      • Sheshego, Limpopo, South Africa, 0742
        • Pfizer Investigational Site
    • Pretoria
      • Mamelodi East, Pretoria, South Africa, 0122
        • Pfizer Investigational Site
  • Tunisia
      • Ariana, Tunisia, 2073
        • Pfizer Investigational Site
      • Bouficha, Tunisia, 4010
        • Pfizer Investigational Site
      • Messaadine, Tunisia, 4013
        • Pfizer Investigational Site
      • Sfax, Tunisia, 3013
        • Pfizer Investigational Site
      • Tunis, Tunisia, 1000
        • Pfizer Investigational Site
      • Zaghouan, Tunisia, 1100
        • Pfizer Investigational Site
  • United Arab Emirates
      • Abu Dhabi, United Arab Emirates
        • Pfizer Investigational Site
      • Al Ain, United Arab Emirates
        • Pfizer Investigational Site
      • Dubai, United Arab Emirates
        • Pfizer Investigational Site
      • Ras Al Khaima, United Arab Emirates
        • Pfizer Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subject selection would be from clinics in a primary care setting

Description

Inclusion Criteria:

  • Adult aged 18 or above

Exclusion Criteria:

  • Pregnant women and/or lactating mothers
  • Subjects presenting with any life threatening disease/condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
Time Frame: At the time of the first visit
At the time of the first visit

Secondary Outcome Measures

Outcome Measure
Time Frame
Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
Time Frame: At the time of the first visit
At the time of the first visit
Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
Time Frame: At the time of the first visit
At the time of the first visit
Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.
Time Frame: At the time of the first visit
At the time of the first visit
Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.
Time Frame: At the time of the first visit
At the time of the first visit
Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.
Time Frame: At the time of the first visit
At the time of the first visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2011

Primary Completion (Actual)

April 1, 2012

Study Completion (Actual)

April 1, 2012

Study Registration Dates

First Submitted

November 12, 2010

First Submitted That Met QC Criteria

November 16, 2010

First Posted (Estimate)

November 18, 2010

Study Record Updates

Last Update Posted (Actual)

February 18, 2021

Last Update Submitted That Met QC Criteria

February 17, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A2581186

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smoking

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe